Halozyme has posted a net loss of $11.8m for the first quarter 2010, or $ 0.13 per diluted share, compared to $14.7m, or $ 0.18 per diluted share, for the comparable period in 2009.
Operating loss was $11.8m, compared to $ 14.7m for the comparable period in 2009.
Jonathan Lim, president and CEO of Halozyme, said: “I am pleased with the progress that Halozyme and its alliance partners, Roche and Baxter, have achieved so far in 2010. The use of our rHuPH20 enzyme in these alliance programs will allow for subcutaneous administration that can potentially improve patient convenience, save healthcare resources, and, in the case of Herceptin SC, reduce the administration time to less than five minutes.”